Janus Capital Management LLC held its stake in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 10,300 shares of the company’s stock at the end of the first quarter. Janus Capital Management LLC’s holdings in Meridian Bioscience were worth $142,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Karp Capital Management Corp bought a new stake in shares of Meridian Bioscience during the first quarter valued at $507,000. Highbridge Capital Management LLC bought a new stake in shares of Meridian Bioscience during the first quarter valued at $1,279,000. State Street Corp increased its stake in shares of Meridian Bioscience by 15.2% in the fourth quarter. State Street Corp now owns 1,080,077 shares of the company’s stock valued at $19,118,000 after buying an additional 142,431 shares during the last quarter. FMR LLC bought a new stake in shares of Meridian Bioscience during the fourth quarter valued at $2,515,000. Finally, Wells Fargo & Company MN increased its position in shares of Meridian Bioscience by 50.2% in the first quarter. Wells Fargo & Company MN now owns 767,606 shares of the company’s stock worth $10,593,000 after buying an additional 256,571 shares in the last quarter. 85.83% of the stock is owned by institutional investors.
Meridian Bioscience Inc. (NASDAQ:VIVO) opened at 13.75 on Friday. Meridian Bioscience Inc. has a one year low of $10.75 and a one year high of $19.85. The company has a 50-day moving average price of $14.84 and a 200-day moving average price of $13.99. The stock has a market cap of $580.29 million, a P/E ratio of 27.50 and a beta of 0.89.
Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.16. The company had revenue of $50.14 million for the quarter, compared to the consensus estimate of $49.13 million. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The firm’s revenue was down 1.0% compared to the same quarter last year. During the same period last year, the business posted $0.21 earnings per share. On average, analysts anticipate that Meridian Bioscience Inc. will post $0.67 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 17th. Stockholders of record on Monday, August 7th will be given a $0.125 dividend. This represents a $0.50 annualized dividend and a dividend yield of 3.64%. The ex-dividend date is Thursday, August 3rd. Meridian Bioscience’s dividend payout ratio is currently 98.04%.
VIVO has been the subject of a number of analyst reports. BidaskClub downgraded Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Thursday, July 6th. Zacks Investment Research downgraded Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Wednesday, June 28th. Finally, Canaccord Genuity increased their price target on Meridian Bioscience from $13.00 to $15.00 and gave the company a “hold” rating in a report on Wednesday, May 3rd. Three investment analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $14.75.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.